Szarkóma: vizsgálatok itt: Kína
106 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Beijing, Hangzhou, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - 3. fázisTaking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiamusi, Jinan, Kunming, Linhai, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Suzhou, Taiyuan, Ürümqi, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Xian, Zhengzhou
- Életkor
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - 2. fázisTaking peopleKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Where
- Chengdu, Nanchang, Nanjing, Shanghai
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Beijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, HangzhouZhejiang, Hefei, Jinan, Nanchang, Nanjing, Shenzhen, Suzhou, Taizhou, Tianjin
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - 1. fázisCsak meghívásosEvaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
See details and how to joinNCT07920822 - 2. fázisTaking peopleA Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 60
- Run by
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
See details and how to joinNCT07920835 - 2. fázisTaking peopleZemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 34
- Run by
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
See details and how to joinNCT07917949 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - No phaseTaking peopleRetroperitoneal Tumor Registry
- Where
- Changchun
- People
- 200
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07915895 - 1/2. fázisNot yet taking people in KínaCombination Immunotherapy Targeting Sarcomas
- Where
- Shenzhen
- Életkor
- 1 év to 75 év
- People
- 20
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04433221 - 1/2. fázisNot yet taking people in KínaSafety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
- Where
- Shenzhen
- Életkor
- 1 év to 75 év
- People
- 20
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03356782 - No phaseNot yet taking people in KínaCTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 60
- Run by
- China-Japan Friendship Hospital
See details and how to joinNCT07902011 - 1. fázisTaking peopleA Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 96
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06531486 - Korai 1. fázisTaking peopleExploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
- Where
- Beijing
- Életkor
- 6 év and over
- People
- 5
- Run by
- Xinxin Zhang
See details and how to joinNCT06932861 - 1. fázisTaking peoplePreliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities
- Where
- Beijing
- Életkor
- 1 év to 18 év
- People
- 16
- Run by
- Beijing Tongren Hospital
See details and how to joinNCT07888114 - No phaseTaking peopleSpatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
- Where
- Jinan
- Életkor
- 18 év to 70 év
- People
- 106
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT06980259 - No phaseCsak meghívásosRadiomics-Based Non-Invasive MRI Differentiation of Uterine Sarcomas and Fibroids
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 520
- Run by
- Tongji Hospital
See details and how to joinNCT07129005 - 1. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
- Where
- Guangzhou, Shanghai, Wuhan
- Életkor
- 18 év and over
- People
- 405 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06884618 · EU 2024-519622-20-00 - 2. fázisNot yet taking people in KínaUtidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
- Where
- Chengdu
- Életkor
- 18 év to 70 év
- People
- 49
- Run by
- Beijing Biostar Pharmaceuticals Co., Ltd.
See details and how to joinNCT07842276 - 1. fázisTaking peopleA Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- Where
- Beijing, Changsha, Hangzhou
- Életkor
- 18 év to 75 év
- People
- 110
- Run by
- Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT06926283 - 2. fázisNot yet taking people in KínaSBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 39
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07817095 - Korai 1. fázisTaking peopleThe Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
- Where
- Wuxi
- Életkor
- 18 év to 75 év
- People
- 10
- Run by
- FindCure Biosciences (ZhongShan) Co., Ltd.
See details and how to joinNCT07459283 - Korai 1. fázisTaking people68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
- Where
- Beijing
- Életkor
- 10 év to 80 év
- People
- 16
- Run by
- Peking University First Hospital
See details and how to joinNCT07774533 - No phaseTaking peopleProspective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
- Where
- Beijing
- Életkor
- 10 év to 60 év
- People
- 100
- Run by
- Peking University People's Hospital
See details and how to joinNCT07725783 - 1. fázisTaking peoplePhase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07374848